# Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals

> **NCT02958982** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rhizen Pharmaceuticals SA** · enrollment: 57 (actual)

## Conditions studied

- Healthy Volunteers
- Asthma

## Interventions

- **DRUG:** RP3128
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02958982
- **Lead sponsor:** Rhizen Pharmaceuticals SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-03
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 57 (ACTUAL)
- **Why stopped:** Significant recruitment delay in POC part
- **Last updated:** 2019-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02958982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02958982, "Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02958982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*